Loading...
Loading...
RXRX| Name | Value |
|---|---|
| Revenues | 13.1M |
| Cost of Revenue | 15.4M |
| Gross Profit | -2.4M |
| Operating Expense | 60.2M |
| Operating I/L | -62.6M |
| Other Income/Expense | 2.1M |
| Interest Income | 1.8M |
| Pretax | -60.4M |
| Income Tax Expense | -2.1M |
| Net Income/Loss | -58.3M |
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company specializing in industrializing drug discovery through the integration of technological innovations across biology, chemistry, automation, data science, and engineering. The company's revenue is generated through the development of various drug candidates, including REC-994 for cerebral cavernous malformation, REC-2282 for neurofibromatosis type 2, REC-4881 for familial adenomatous polyposis, and REC-3599 for GM2 gangliosidosis, as well as several preclinical stage products targeting conditions such as Clostridium difficile colitis, ovarian cancer, and immune checkpoint resistance in non-small cell lung cancer.
